VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viking Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$25.05−0.12 (-0.48%)
Close on Oct 19, 2026
- Market cap
- $2.91B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
64.9%
76M of 117M shares
Institutional holders
434
75 new, 50 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
1 buys · 20 sales
Net sold $22.10M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vanguard Capital Management | 5,877,263 | 5.08% | 13G (passive) | Mar 31, 2026 |
| FMR LLC | 5,772,051 | 5.10% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson | 11,249,337 | 10.00% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VKTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 6,335,756 | 5.43% | $247.16M | +311,003 | 0.01% |
| BlackRock, Inc. | 6,189,649 | 5.31% | $241.46M | −690,641 | 0.00% |
| State Street Corp | 5,606,394 | 4.81% | $218.71M | +1,210,837 | 0.01% |
| Vanguard Capital Management LLC | 5,053,663 | 4.33% | $197.14M | +41,161 | 0.00% |
| Vanguard Portfolio Management LLC | 4,484,263 | 3.84% | $174.93M | +19,965 | 0.01% |
| Two Sigma Investments, LP | 3,937,414 | 3.38% | $153.60M | −494,728 | 0.11% |
| Morgan Stanley | 3,486,040 | 2.99% | $135.99M | +472,112 | 0.01% |
| Ameriprise Financial Inc | 2,156,083 | 1.85% | $84.11M | +477,338 | 0.02% |
| Geode Capital Management, LLC | 2,097,981 | 1.80% | $81.87M | +15,914 | 0.00% |
| American Century Companies Inc | 1,816,050 | 1.56% | $70.84M | −262,527 | 0.03% |
| D. E. Shaw & Co., Inc. | 1,605,994 | 1.38% | $62.65M | −70,719 | 0.03% |
| Bnp Paribas Arbitrage, Snc | 981,700 | 0.84% | $38.30M | +441,201 | 0.01% |
| Citadel Advisors LLC | 951,515 | 0.82% | $37.12M | −310,706 | 0.00% |
| Goldman Sachs Group Inc | 942,841 | 0.81% | $36.78M | −17,729 | 0.00% |
| UBS Group AG | 936,055 | 0.80% | $36.52M | −411,417 | 0.00% |
| JPMorgan Chase & Co | 915,185 | 0.78% | $36.39M | +429,482 | 0.00% |
| Jane Street Group, LLC | 899,558 | 0.77% | $35.09M | +150,609 | 0.00% |
| Susquehanna International Group, Llp | 816,367 | 0.70% | $31.85M | +110,558 | 0.00% |
| Raymond James Financial Inc | 794,660 | 0.68% | $31.00M | −1,280,743 | 0.01% |
| Vanguard Fiduciary Trust Co | 732,047 | 0.63% | $28.56M | +21,635 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 434 | 76M | 64.9% | 75 / 144 | 131 / 50 | 9M | 7M |
| Q1 2026 | 414 | 73M | 62.9% | 67 / 155 | 118 / 71 | 21M | 10M |
| Q4 2025 | 426 | 72M | 61.8% | 112 / 115 | 134 / 44 | 13M | 14M |
| Q3 2025 | 370 | 74M | 63.3% | 51 / 142 | 108 / 69 | 13M | 16M |
| Q2 2025 | 391 | 77M | 65.9% | 82 / 149 | 109 / 59 | 12M | 13M |
| Q1 2025 | 372 | 78M | 67.0% | 66 / 161 | 99 / 99 | 12M | 15M |
| Q4 2024 | 408 | 82M | 70.3% | 82 / 147 | 127 / 88 | 10M | 13M |
| Q3 2024 | 422 | 86M | 73.8% | 95 / 178 | 101 / 57 | 17M | 8M |
| Q2 2024 | 387 | 83M | 70.9% | 91 / 165 | 102 / 72 | 16M | 17M |
| Q1 2024 | 373 | 83M | 71.6% | 202 / 78 | 86 / 26 | 27M | 23M |
| Q4 2023 | 197 | 79M | 67.3% | 48 / 61 | 54 / 30 | 12M | 11M |
| Q3 2023 | 179 | 77M | 66.3% | 31 / 63 | 49 / 43 | 12M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of VKTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,587,998 | 3.08% | $139.97M | 1.30% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,500,175 | 3.00% | $136.54M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,528,235 | 2.17% | $98.63M | 0.05% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,458,461 | 1.25% | $56.89M | 0.12% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,333,178 | 1.14% | $52.01M | 0.05% | Jun 30, 2026 |
| Heritage Fund | 1,331,574 | 1.14% | $42.26M | 0.80% | Jul 31, 2026 |
| Fidelity Advisor Growth Opportunities Fund | 1,062,178 | 0.91% | $34.78M | 0.10% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 598,010 | 0.51% | $19.58M | 0.05% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 555,687 | 0.48% | $18.19M | 0.08% | May 31, 2026 |
| Select Health Care Portfolio | 540,000 | 0.46% | $17.68M | 0.31% | May 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 537,400 | 0.46% | $17.06M | 0.23% | Jul 31, 2026 |
| iShares Russell Mid-Cap ETF | 467,194 | 0.40% | $18.23M | 0.03% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 450,187 | 0.39% | $14.29M | 0.65% | Jul 31, 2026 |
| Vanguard Explorer Fund | 444,125 | 0.38% | $14.10M | 0.06% | Jul 31, 2026 |
| Fidelity Mid Cap Index Fund | 428,648 | 0.37% | $13.61M | 0.03% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brian Lian | President & CEO, Director | 2,572,441 | 2.21% | Jul 29, 2026 |
| Greg Zante | Chief Financial Officer | 212,204 | 0.18% | Jul 29, 2026 |
| Marianna Mancini | Chief Operating Officer | 422,760 | 0.36% | Jul 29, 2026 |
| Hubert C. Chen | Chief Medical Officer | – | – | Jun 3, 2026 |
| Neil William Aubuchon | Chief Commercial Officer | 4,475 | 0.00% | Mar 10, 2026 |
| Dorothy Elizabeth Kelly-Gemmell | Director | 6,333 | 0.01% | Aug 7, 2026 |
| Lawson Macartney | Director | 51,115 | 0.04% | Jan 5, 2026 |
| Matthew W. Foehr | Director | 132,036 | 0.11% | Jan 5, 2026 |
| Sarah Kathryn Rouan | Director | 4,390 | 0.00% | Jan 5, 2026 |
| Charles A. Rowland Jr | Director | 33,150 | 0.03% | Jan 5, 2026 |
| J. Matthew Singleton | Director | 12,650 | 0.01% | Jan 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dorothy Elizabeth Kelly-Gemmell Director | Aug 1, 2026 | Award | +6,333 | – | – | 6,333 |
| Brian Lian President & CEO, Director | Jul 29, 2026 | Sale | −148,517 | $33.32 | $4.95M | 2,572,441 |
| Marianna Mancini Chief Operating Officer | Jul 29, 2026 | Sale | −18,217 | $33.47 | $609.72K | 422,760 |
| Greg Zante Chief Financial Officer | Jul 29, 2026 | Sale | −21,217 | $33.47 | $710.13K | 212,204 |
| Brian Lian President & CEO, Director | Jul 28, 2026 | Award | +221,667 | – | – | 2,720,958 |
| Marianna Mancini Chief Operating Officer | Jul 28, 2026 | Award | +31,667 | – | – | 440,977 |
| Greg Zante Chief Financial Officer | Jul 28, 2026 | Award | +31,667 | – | – | 233,421 |
| Neil William Aubuchon Chief Commercial Officer | Mar 10, 2026 | Buy | +4,475 | $33.50 | $149.91K | 4,475 |
| Greg Zante Chief Financial Officer | Jan 5, 2026 | Sale | −1,500 | $32.09 | $48.14K | 189,891 |
| Greg Zante Chief Financial Officer | Jan 5, 2026 | Sale | −10,300 | $34.24 | $352.67K | 191,371 |
| Greg Zante Chief Financial Officer | Jan 5, 2026 | Sale | −13,900 | $33.38 | $463.98K | 201,671 |
| Greg Zante Chief Financial Officer | Jan 5, 2026 | Sale | −31,961 | $32.30 | $1.03M | 215,571 |
| Marianna Mancini Chief Operating Officer | Jan 5, 2026 | Sale | −1,600 | $35.07 | $56.11K | 409,190 |
| Marianna Mancini Chief Operating Officer | Jan 5, 2026 | Sale | −10,500 | $34.22 | $359.31K | 410,790 |
| Marianna Mancini Chief Operating Officer | Jan 5, 2026 | Sale | −13,600 | $33.37 | $453.83K | 421,290 |
| Marianna Mancini Chief Operating Officer | Jan 5, 2026 | Sale | −31,961 | $32.29 | $1.03M | 434,890 |
| Brian Lian President & CEO, Director | Jan 5, 2026 | Sale | −132,454 | $32.29 | $4.28M | 2,600,246 |
| Brian Lian President & CEO, Director | Jan 5, 2026 | Sale | −41,276 | $34.22 | $1.41M | 2,505,691 |
| Brian Lian President & CEO, Director | Jan 5, 2026 | Sale | −53,279 | $33.38 | $1.78M | 2,546,967 |
| Brian Lian President & CEO, Director | Jan 5, 2026 | Sale | −6,400 | $35.07 | $224.45K | 2,499,291 |
| Sarah Kathryn Rouan Director | Jan 2, 2026 | Award | +3,150 | – | – | 4,390 |
| J. Matthew Singleton Director | Jan 2, 2026 | Award | +3,150 | – | – | 12,650 |
| Lawson Macartney Director | Jan 2, 2026 | Award | +3,150 | – | – | 51,115 |
| Charles A. Rowland Jr Director | Jan 2, 2026 | Award | +3,150 | – | – | 33,150 |
| Greg Zante Chief Financial Officer | Jan 2, 2026 | Award | +32,049 | – | – | 247,532 |
| Greg Zante Chief Financial Officer | Jan 2, 2026 | Award | +41,000 | – | – | 215,483 |
| Marianna Mancini Chief Operating Officer | Jan 2, 2026 | Award | +32,049 | – | – | 466,851 |
| Marianna Mancini Chief Operating Officer | Jan 2, 2026 | Award | +41,000 | – | – | 434,802 |
| Brian Lian President & CEO, Director | Jan 2, 2026 | Award | +78,400 | – | – | 2,508,620 |
| Brian Lian President & CEO, Director | Jan 2, 2026 | Award | +224,080 | – | – | 2,732,700 |
| Matthew W. Foehr Director | Jan 2, 2026 | Sale | −16,000 | $35.11 | $561.76K | 132,036 |
| Matthew W. Foehr Director | Jan 2, 2026 | Option exercise | +16,000 | $3.33 | $53.28K | 148,036 |
| Matthew W. Foehr Director | Jan 2, 2026 | Award | +3,150 | – | – | 135,186 |
| Marianna Mancini Chief Operating Officer | Oct 28, 2025 | Sale | −6,185 | $35.00 | $216.48K | 382,467 |
| Brian Lian President & CEO, Director | Oct 28, 2025 | Sale | −38,989 | $35.01 | $1.37M | 2,419,109 |
| Greg Zante Chief Financial Officer | Oct 28, 2025 | Sale | −6,185 | $35.00 | $216.48K | 173,592 |
| Marianna Mancini Chief Operating Officer | Oct 27, 2025 | Award | +11,117 | – | – | 388,652 |
| Brian Lian President & CEO, Director | Oct 27, 2025 | Award | +70,084 | – | – | 2,458,098 |
| Greg Zante Chief Financial Officer | Oct 27, 2025 | Award | +11,117 | – | – | 179,777 |
| Charles A. Rowland Jr Director | Oct 27, 2025 | Award | +16,000 | $4.48 | $71.68K | 46,000 |
| Charles A. Rowland Jr Director | Oct 27, 2025 | Award | +22,000 | $5.80 | $127.60K | 68,000 |
| Charles A. Rowland Jr Director | Oct 27, 2025 | Award | +22,000 | $4.88 | $107.36K | 90,000 |
| Charles A. Rowland Jr Director | Oct 27, 2025 | Sale | −60,000 | $35.57 | $2.13M | 30,000 |
| Brian Lian President & CEO, Director | Jul 3, 2025 | Sale | −26,889 | $27.80 | $747.51K | 2,388,014 |
| Marianna Mancini Chief Operating Officer | Jul 3, 2025 | Sale | −4,266 | $27.77 | $118.47K | 377,535 |
| Greg Zante Chief Financial Officer | Jul 3, 2025 | Sale | −4,266 | $27.76 | $118.42K | 168,660 |
| Brian Lian President & CEO, Director | Jul 2, 2025 | Award | +48,333 | – | – | 2,414,903 |
| Marianna Mancini Chief Operating Officer | Jul 2, 2025 | Award | +7,667 | – | – | 381,801 |
| Greg Zante Chief Financial Officer | Jul 2, 2025 | Award | +7,667 | – | – | 172,926 |
| Matthew W. Foehr Director | Apr 11, 2025 | Option exercise | +20,786 | $8.00 | $166.29K | 132,036 |
| Sarah Kathryn Rouan Director | Mar 31, 2025 | Buy | +1,240 | $24.15 | $29.95K | 1,240 |
| Sarah Kathryn Rouan Director | Mar 31, 2025 | Buy | +1,240 | $24.15 | $29.95K | 1,240 |
| Brian Lian President & CEO, Director | Jan 6, 2025 | Sale | −175,490 | $42.68 | $7.49M | 2,385,570 |
| Brian Lian President & CEO, Director | Jan 6, 2025 | Sale | −19,000 | $43.32 | $823.08K | 2,366,570 |
| Greg Zante Chief Financial Officer | Jan 6, 2025 | Sale | −45,609 | $42.69 | $1.95M | 169,959 |
| Greg Zante Chief Financial Officer | Jan 6, 2025 | Sale | −4,700 | $43.32 | $203.60K | 165,259 |
| Marianna Mancini Chief Operating Officer | Jan 6, 2025 | Sale | −5,100 | $43.32 | $220.93K | 374,134 |
| Marianna Mancini Chief Operating Officer | Jan 6, 2025 | Sale | −49,115 | $42.69 | $2.10M | 379,234 |
| Brian Lian President & CEO, Director | Jan 3, 2025 | Award | +163,333 | – | – | 2,561,060 |
| Brian Lian President & CEO, Director | Jan 3, 2025 | Award | +92,800 | – | – | 2,397,727 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Zante Greg Officer | Jul 29, 2026 | 21,217 | $710.14K | Jul 29, 2026 | Performance Stock Units |
| Mancini Marianna Officer | Jul 29, 2026 | 18,217 | $609.64K | Jul 29, 2026 | Performance Stock Units |
| Lian Brian Officer | Jul 29, 2026 | 148,517 | $4.95M | Jul 29, 2026 | Performance Stock Units |
| Lian Brian Officer | Jan 5, 2026 | 233,409 | $7.69M | Jan 5, 2026 | Performance Stock Units |
| Zante Greg Officer | Jan 5, 2026 | 57,661 | $1.90M | Jan 5, 2026 | Performance Stock Units |
| Mancini Marianna Officer | Jan 5, 2026 | 57,661 | $1.90M | Jan 5, 2026 | Restricted stock vesting under a registered plan |
| W. Foehr Matthew Director | Jan 2, 2026 | 16,000 | $561.69K | Jan 2, 2026 | Exercise of options under a registered plan |
| Zante Greg Officer | Oct 28, 2025 | 6,185 | $216.53K | Oct 28, 2025 | Performance Stock Units |
| Mancini Marianna Officer | Oct 28, 2025 | 6,185 | $216.49K | Oct 28, 2025 | Performance Stock Units |
| Lian Brian Officer | Oct 28, 2025 | 38,989 | $1.36M | Oct 28, 2025 | Performance Stock Units |
| A. Rowland Charles Jr. Director | Oct 27, 2025 | 60,000 | $2.13M | Oct 27, 2025 | Exercise of options under a registered plan |
| Lian Brian Officer | Jul 3, 2025 | 26,889 | $747.63K | Jul 3, 2025 | Restricted stock vesting under a registered plan |
| Mancini Marianna Officer | Jul 3, 2025 | 4,266 | $118.47K | Jul 3, 2025 | Restricted stock vesting under a registered plan |
| Zante Greg Officer | Jul 3, 2025 | 4,266 | $118.43K | Jul 3, 2025 | Restricted stock vesting under a registered plan |
| Mancini Marianna Officer | Jan 6, 2025 | 54,215 | $2.32M | Jan 6, 2025 | Restricted stock vesting under a registered plan |